Scynexis (SCYX) Liabilities and Shareholders Equity (2013 - 2026)
Scynexis' (SCYX) quarterly Liabilities and Shareholders Equity came in at $77.6 million in Q1 2026, up 14.3% YoY from $67.9 million in Q1 2025, and up 31.51% on a QoQ basis from $59.0 million in Q4 2025.
Scynexis (SCYX) Liabilities and Shareholders Equity (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $77.6 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 14.3% year-over-year to $77.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $248.4 million (down 32.02% YoY) and the FY2025 annual result came in at $59.0 million, down 34.88% from the prior year.
- Liabilities and Shareholders Equity climbed to $77.6 million in Q1 2026, from $59.0 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $154.9 million in Q2 2023 to a low of $51.1 million in Q3 2025.
- A 5-year average of $98.9 million and a median of $99.0 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity surged 68.22% — and 2025, when it slumped 48.43%.
- Tracing SCYX's Liabilities and Shareholders Equity over 5 years: stood at $87.8 million in 2022, then soared by 46.24% to $128.4 million in 2023, then decreased by 29.41% to $90.6 million in 2024, then sank by 34.88% to $59.0 million in 2025, then jumped by 31.51% to $77.6 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $77.6 million (Q1 2026), $59.0 million (Q4 2025), and $51.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 6.18 Bn |
| 10 | Scynexis | 61.37 Mn | -53.33 Mn | - | 74.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 74.97 Mn |
| Mar 31, 2026 | 77.63 Mn |
| Dec 31, 2025 | 59.03 Mn |
| Sep 30, 2025 | 51.07 Mn |
| Jun 30, 2025 | 60.69 Mn |
| Mar 31, 2025 | 67.92 Mn |
| Dec 31, 2024 | 90.64 Mn |
| Sep 30, 2024 | 99.04 Mn |
| Jun 30, 2024 | 107.81 Mn |
| Mar 31, 2024 | 118.25 Mn |
| Dec 31, 2023 | 128.41 Mn |
| Sep 30, 2023 | 148.55 Mn |
| Jun 30, 2023 | 154.86 Mn |
| Mar 31, 2023 | 70.30 Mn |
| Dec 31, 2022 | 87.81 Mn |
| Sep 30, 2022 | 112.29 Mn |
| Jun 30, 2022 | 135.61 Mn |
| Mar 31, 2022 | 111.56 Mn |
| Dec 31, 2021 | 119.84 Mn |
| Sep 30, 2021 | 109.88 Mn |